Agalsidase beta

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Apr 1, 2012 → Mar 1, 2013

NCT ID

NCT01650779

About Agalsidase beta

Agalsidase beta is a approved stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01650779. Target conditions include Fabry Disease.

What happened to similar drugs?

8 of 20 similar drugs in Fabry Disease were approved

Approved (8) Terminated (4) Active (11)

✅agalsidase betaSanofiApproved

✅Fabrazyme (agalsidase beta)SanofiApproved

✅agalsidase betaSanofiApproved

✅AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved

✅agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved

✅Agalsidase betaSanofiApproved

✅Fabrazyme (agalsidase beta) + PlaceboSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05054387	Approved	Completed	Oct 13, 2021	Mar 9, 2023	Fabry Disease
NCT01650779	Approved	Completed	Apr 1, 2012	Mar 1, 2013	Fabry Disease
NCT00230607	Approved	Terminated	May 28, 2006	Feb 9, 2024	Fabry Disease
NCT00140621	Approved	Completed	Jul 1, 2005	Aug 1, 2012	Fabry Disease
NCT00081497	Approved	Completed	Jan 1, 2004	Sep 1, 2005	Fabry Disease

Competing Products

20 competing products in Fabry Disease

See all competitors

Product	Company	Stage	Hype Score
Lucerastat	Idorsia	Phase 3	38
Fabrazyme (agalsidase beta)	Sanofi	Phase 2	35
Venglustat (GZ402671) + Placebo	Sanofi	Phase 3	44
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)	Sanofi	Phase 2	27
agalsidase beta	Sanofi	Approved	35
Tropicamide	Sanofi	Pre-clinical	26
Fabrazyme (agalsidase beta)	Sanofi	Approved	35
agalsidase beta	Sanofi	Approved	43
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine	Sanofi	Approved	43
Gabapentin + placebo	Sanofi	Phase 2	27
GZ/SAR402671	Sanofi	Phase 2	35
agalsidase beta (GZ419828) + agalsidase alfa	Sanofi	Approved	35
Fabrazyme (agalsidase beta)	Sanofi	Phase 3	40
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat	Sanofi	Phase 3	44
Iohexol	Sanofi	Phase 1	21
GZ/SAR402671	Sanofi	Phase 2	35
Fabrazyme (agalsidase beta)	Sanofi	Phase 2	35
Agalsidase beta	Sanofi	Approved	43
Fabrazyme (agalsidase beta) + Placebo	Sanofi	Approved	43
Agalsidase beta + Agalsidase beta	Sanofi	Phase 3	40